OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) And STENOCARE Sign An MOU

OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) And STENOCARE Sign An MOU

OWC
Pharmaceutical Research Corp (OTCMKTS:OWCP)

and STENOCARE are into a new progressive deal. The two business giants just
moved into a Memorandum of Understanding (MoU) that is quite strategic. These
two seek to engage in the development and the commercialization of some
wide-ranging cannabis-based medical products.

Terms of
the deal

Each of the parties will have something to gain
from the deal. For instance, OWC’s technologies will benefit from a more
expansive market. On the other hand, the business strategy of STENOCARE might
end up becoming a huge success. The business guru has been looking forward to
supplementing its top-quality generic medical cannabis products. Its target has
been to supplement them with differentiated products meant to treat numerous
patient groups struggling with particular serious conditions.

The new cooperation means well for them, considering
that they will increase their sales massively. They will also be able to
distribute products in large volumes within the existing core markets of
STENOCARE. The businesses also want to venture into new territories in their
quest to boost their business profits.

STENOCARE
and its plans

STENOCARE expresses its willingness to deliver some
top quality cannabis raw materials. Asides from that, it will also be seeking
to provide extensive knowledge in line with the supply and the distribution of
the medical cannabis-based products in Ireland and Denmark as well.

On the other hand, OWC Pharmaceutical says it will
offer its expertise in clinical trials and medical research. The business has
been focusing on cannabis products providing therapeutic solutions to patients.
It prides itself on having in place what it terms an extensive Intellectual
Property Portfolio.

The first
product candidate

The information regarding the first product
candidate for this collaboration is already out. This will be a sublingual tablet
pulling along with specified medical cannabis ratios vital in meeting up to the
needs of patients. It will be important to make the appropriate diagnosis as
well as check out how they will be responding to treatment.

The CEO of OWC Pharmaceutical Research Mordechai
Bignitz says that STENOCARE is a great choice for a partner. He says that
considering the company’s capacity in the distribution of medical cannabis
products to some interesting markets. This official also speaks about the focus
on pharma-grade production.

Published at Mon, 25 Nov 2019 13:01:00 +0000

Leave a Reply

Your email address will not be published. Required fields are marked *